D-0636-2020 Class I Terminated
FDA drug recall D-0636-2020 was initiated by AuroMedics Pharma LLC on Nov 20, 2019 and is designated Class I. Reason for recall: Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets. The recall status is terminated (terminated Feb 21, 2024).
Recall Details
- Product Type
- Drugs
- Report Date
- Dec 18, 2019
- Initiation Date
- Nov 20, 2019
- Termination Date
- Feb 21, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
Product Description
Mirtazapine Tablets, USP, 15 mg, 500-count tablets, Rx only, Distributed by: Aurobindo Pharma USA, Inc. Dayton, NJ 08810 NDC 13107-031-05
Reason for Recall
Labeling: Label Error on Declared Strength; cases labelled Mirtazapine 15mg tablets, 500-count bottles, contain 500-count bottles of Mirtazapine 15mg tablets labelled as Mirtazapine 7.5 mg tablets.
Distribution Pattern
Nationwide
Code Information
Lot #: 03119002A3, Exp 3/2022
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0636-2020
- openFDA file date
- Nov 3, 2026
- Loaded by RegDataLab
- Nov 4, 2026